No abstract

Aim: To analyze prevalence and type of symptomatic gastrointestinal involvement during symptomatic COVID-19 (up to 412 weeks after the disease) and post-COVID-19 syndrome (more than 12 weeks from the disease onset). Materials and methods: We retrospectively analyzed the data from 785 in-patients with the diagnosis of COVID-19, who were treated in the infectious disease hospital from May to December 2020. At the first phase of the study we analyzed how frequently they were referred for out-patient care by a gastroenterology specialist after they were discharged from the hospital (all 785 patient medical files). At the 2nd study phase we performed phone calls to 247 patients, that were discharged from the infectious disease hospital, during which a specially designed questionnaire was filled with items on their comorbidities, general and specific complaints, as well as the standardized Gastrointestinal Symptom Rating Scale (GSRS). Results: Within 2 years after their discharge from the infectious disease hospital, 88 patients asked for specialized gastroenterological care on an out-patient basis. The most common diagnoses were pancreatic diseases (33%), gastric disorders (31%), intestinal disorders (25%), liver and biliary disorders (11%). At referral, the most common complaints were dyspeptic: nausea, bitter taste in the mouth, heartburn, bloating (25%), abdominal pains of various location (17%) and stool abnormalities, such as diarrhea and constipation (11%). Among patients who participated in the phone survey (N = 247), symptomatic COVID-19 was observed in 90 (11.46%) cases, with predominant complaints being loss of taste, loss of smell, and fever. Post-COVID-19 syndrome was identified in 157 (20%) cases, with their main complaints being weakness, shortness of breath and joint pain. Stool abnormalities and abdominal pain occurred during symptomatic COVID-19 and in the post-COVID-19 period with the same frequency (9% and 10%, respectively). According to the GSRS results, the post-COVID-19 dyspeptic syndrome was characterized by prevailing complaints of heartburn (24%), upper abdominal pain and discomfort (20%), and bloating (15%). Conclusion: In the patients with a history of COVID-19, along with respiratory syndromes, gastrointestinal symptoms are seen, with their types being variable at various period of the coronavirus infection. In the early COVID-19, these are stool abnormalities and abdominal pain, and during the post-COVID-19 syndrome, nausea, bitter taste in the mouth, heartburn and bloating are more common.

Introduction. Joint hypermobility is a common polyetiological condition that can be accompanied by pain in the joints and lead to the early onset of osteoarthritis. The study of the comorbidity of JH and somatic pathology, in connective tissue dysplasia, is fragmentary and relevant for optimizing the classification and criteria for early diagnosis of this condition. Aim. Analysis of the frequency of phenotypic signs of uCTD in individuals with JH.Materials and methods. A cross-sectional study of 35 men (21.77 ± 0.60 years) and 226 women (21.42 ± 0.18 years) was carried out. 2 groups were formed – with the presence of HMS (n = 156) and the control group (n = 105). JH was determined according to the Beighton scale, phenotypic signs of uCTD – according to the modified table by T. Kadurina.Results. Statistically significant differences were found in the frequency of occurrence of phenotypic signs of CTD in individuals with hypermobility – a decrease in BMI < 18 kg/m2 (p = 0.0001), skin hyperelasticity (p = 0.0001), ptosis of internal organs (p = 0.038), dolichostenomyelia (p = 0.010), hyperkyphosis/hyperlordosis (p = 0.003), joint crunch (p = 0.009), GERD (p = 0.021) and arterial hypotension (p = 0.0001). Mild myopia was more common in the control group (p = 0.020), and severe myopia was more common in the JH group (p = 0.003). Keloid scars were more common in the group with severe JH (p = 0.021).Conclusions. In patients with joint hypermobility, phenotypic manifestations of connective tissue dysplasia were revealed, most often involving the musculoskeletal system (dolichostenomelia, crunching in the joints, curvature of the spine) and skin (hyperelasticity, keloid scars).

This article provides a review of the literature on such a relevant topic in the epidemiological situation, on the impact of COVID-19 on the digestive organs and post-covid manifestations from the gastrointestinal tract. A review of more than 15 international literature sources and metadata is presented, reliable factors about post-COVID manifestations are given. Depending on the course and duration of COVID-19, definitions of the diagnosis are presented. It also presents the multi-system nature of Post-COVID. The main purpose of this article is to review the literature and metadata from sources to assess the impact of COVID-19 on the gastrointestinal tract and the nature of post-COVID gastrointestinal manifestations. The COVID-19 pandemic has gripped millions of people around the world, leaving a global burden. Therefore, it is important to continue studying the theoretical and clinical foundations of the disease, both in the main period of the disease, and multiple organ manifestations of COVID-19, as systemic pathophysiological consequences. The main conclusion of this article can reasonably be said about the negative impact of SARS-CoV-2 on the gastrointestinal tract in the acute period, as well as the long-term effects of the virus on the gastrointestinal tract. The digestive organs, as well as the respiratory organs, are the entrance gates of the virus.

The immune reactivity of patients with pollinosis in remission is studied. The significant impairment of cellular and humoral immunity is found in patients with pollinosis. The obtained data that characterize the immune reactivity do not link with sex and regional settlement. The investigation reveals the necessity of immune correction in patients with pollinosis.